Cytokinetics (CYTK) Tops Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $82.24 --0%
Revenue Growth %: -74.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
CCEL, FNGR, FAST, More
Revenue Growth %: -74.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Neutral Rating on Wingstop (WING), Expects Q2 to Reflect Pressured Sales Trends
- UBS Reiterates Buy Rating on Boeing (BA) on Increased Confidence in 2026 Deliveries
- Karman Space & Defense invests $2.7M to expand Pennsylvania facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
